José Sullivan López-González

Author

Instituto Nacional de Enfermedades Respiratorias ORCID

Also Known As

GONZÁLEZ, J., J GONZÁLEZ, J S López González, J. López-González, J. S. Lopez-Gonzalez, J.S. Lopez-Gonzalez, J.S. LÓPEZ-GONZÁLEZ, J.S. López-González, JOSÉ SULLIVAN LÓPEZ-GONZÁLEZ, Jose Gonzalez

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Instituto Nacional de Enfermedades Respiratorias Universidad Nacional Autónoma de México Instituto Politécnico Nacional National Institute of Genomic Medicine Centro Medico Nacional Siglo XXI

About

José Sullivan López-González is an author at Instituto Nacional de Enfermedades Respiratorias specializing in medicine, cancer research, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	656
2	Cell Biology	9	9	326
3	Immunology	8	8	325
4	Pathology	4	4	114
5	Health Sciences	2	2	66

José Sullivan López-González

Publications

801

Citations

H-Index

Page 1

	Year	Citations
Apoptosis and cell cycle disturbances induced by coumarin and 7-hydroxycoumarin on human lung carcinoma cell lines José Sullivan López-González, Heriberto Prado-Garcı́a, Dolores Aguilar‐Cázares, Lung Cancer Chemoprevention StrategyOncogenic AgentMedicineApoptosisPharmacology	2004	132
MONOCLONAL ANTIBODIES AND CANCER José Sullivan López-González, M Selman Lama InPharma Tumor ImmunologyImmunologyMonoclonal AntibodiesAntibody EngineeringImmunotherapy	1982	122
Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin Fausto Alejandro Jiménez-Orozco, José Sullivan López-González, Alejandro Nieto, Lung Cancer Tumor BiologyOncogenic AgentCyclin D1MedicinePharmacology	2001	61
Effector, memory and naïve CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients Heriberto Prado-Garcı́a, Dolores Aguilar‐Cázares, Hector Flores-Vergara, Lung Cancer Immunological MemoryCancer ImmunosurveillanceImmunologyPathologyPeripheral Blood	2004	55
[National consensus of diagnosis and treatment of non-small cell lung cancer]. Óscar Arrieta, Enrique Guzmán-de Alba, Luis Felipe Alba-López, PubMed Translational MedicineSurgical OncologyLung Cancer TreatmentAdvanced Lung DiseaseMedicine	2013	46
Cooperative multi-targeting of signaling networks by angiomiR-204 inhibits vasculogenic mimicry in breast cancer cells Yarely M. Salinas-Vera, Laurence A. Marchat, Raúl García-Vázquez, Cancer Letters Cooperative Multi-targetingAngiogenesisBreast Cancer CellsBreast CancerVascular Biology	2018	44
Lung squamous cell carcinoma and adenocarcinoma cell lines use different mediators to induce comparable phenotypic and functional changes in human monocyte-derived dendritic cells Federico Ávila‐Moreno, José Sullivan López-González, Griselda Galindo-Rodrı́guez, Cancer Immunology Immunotherapy Cancer ImmunosurveillanceImmunologyBiological MicroenvironmentsImmunoeditingAdenocarcinoma Cell Lines	2005	33
Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors Vivek Subbiah, William D. Erwin, Osama Mawlawi, Clinical Cancer Research	2020	28
The novel immunomodulator IMMUNEPOTENT CRP combined with chemotherapy agent increased the rate of immunogenic cell death and prevented melanoma growth María del Carmen Rodríguez‐Salazar, Moisés Ármides Franco-Molina, Edgar Mendoza-Gamboa, Oncology Letters	2017	26
Activation-induced cell death of memory CD8+ T cells from pleural effusion of lung cancer patients is mediated by the type II Fas-induced apoptotic pathway Heriberto Prado-Garcı́a, Susana Romero‐Garcia, Jorge Morales-Fuentes, Cancer Immunology Immunotherapy ApoptosisImmunologyCell DeathPleural EffusionBronchial Neoplasm	2011	25

Page 1